[Federal Register Volume 82, Number 89 (Wednesday, May 10, 2017)]
[Notices]
[Page 21811]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-09450]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Office of the Secretary


Uniform Formulary Beneficiary Advisory Panel; Notice of Federal 
Advisory Committee Meeting

AGENCY: Assistant Secretary of Defense (Health Affairs), Department of 
Defense.

ACTION: Notice of Federal Advisory Committee meeting.

-----------------------------------------------------------------------

SUMMARY: The Department of Defense (DoD) is publishing this notice to 
announce that the following Federal Advisory Committee meeting of the 
Uniform Formulary Beneficiary Advisory Panel will take place.

DATES: Open to the public Thursday, June 22, 2017 from 9:00 a.m. to 
12:00 p.m.

ADDRESSES: The address of the open meeting is Naval Heritage Center 
Theater, 701 Pennsylvania Avenue NW., Washington, DC 20004.

FOR FURTHER INFORMATION CONTACT: Edward Norton, 703-681-2890 (Voice), 
703-681-1940 (Facsimile), [email protected] 
(Email). Mailing address is 7700 Arlington Boulevard, Suite 5101, Falls 
Church, VA 22042-5101. Web site: http://www.health.mil/About-MHS/Other-MHS-Organizations/Beneficiary-Advisory-Panel. The most up-to-date 
changes to the meeting agenda can be found on the Web site.

SUPPLEMENTARY INFORMATION: This meeting is being held under the 
provisions of the Federal Advisory Committee Act (FACA) of 1972 (5 
U.S.C., Appendix, as amended), the Government in the Sunshine Act of 
1976 (5 U.S.C. 552b, as amended), and 41 CFR 102-3.140 and 102-3.150.
    Purpose of the Meeting: The Department of Defense is publishing 
this notice to announce a Federal Advisory Committee meeting of the 
Uniform Formulary Beneficiary Advisory Panel (hereafter referred to as 
the Panel).
    Agenda:
    1. Sign-In.
    2. Welcome and Opening Remarks.
    3. Public Citizen Comments.
    4. Scheduled Therapeutic Class Reviews (Comments will follow each 
agenda item).
    a. Ophthalmic-1 Agents.
    b. Pulmonary Miscellaneous.
    5. Newly Approved Drugs Review.
    6. Pertinent Utilization Management Issues.
    7. Panel Discussions and Vote.
    Meeting Accessibility: Pursuant to 5 U.S.C. 552b, as amended, and 
41 Code of Federal Regulations (CFR) 102-3.140 through 102-3.165, and 
the availability of space, this meeting is open to the public. Seating 
is limited and will be provided only to the first 220 people signing-
in. All persons must sign-in legibly.
    Written Statements: Pursuant to 41 CFR 102-3.140, the public or 
interested organizations may submit written statements to the 
membership of the Panel at any time or in response to the stated agenda 
of a planned meeting. Written statements should be submitted to the 
Panel's Designated Federal Officer (DFO). The DFO's contact information 
can be obtained from the General Services Administration's Federal 
Advisory Committee Act Database at http://facadatabase.gov/. Written 
statements that do not pertain to the scheduled meeting of the Panel 
may be submitted at any time. However, if individual comments pertain 
to a specific topic being discussed at a planned meeting, then these 
statements must be submitted no later than 5 business days prior to the 
meeting in question. The DFO will review all submitted written 
statements and provide copies to all the committee members.
    Public Comments: In addition to written statements, the Panel will 
set aside 1 hour for individuals or interested groups to address the 
Panel. To ensure consideration of their comments, individuals and 
interested groups should submit written statements as outlined in this 
notice; but if they still want to address the Panel, then they will be 
afforded the opportunity to register to address the Panel. The Panel's 
DFO will have a ``Sign-Up Roster'' available at the Panel meeting for 
registration on a first-come, first-serve basis. Those wishing to 
address the Panel will be given no more than 5 minutes to present their 
comments, and at the end of the 1-hour time period, no further public 
comments will be accepted. Anyone who signs-up to address the Panel, 
but is unable to do so due to the time limitation, may submit their 
comments in writing; however, they must understand that their written 
comments may not be reviewed prior to the Panel's deliberation. To 
ensure timeliness of comments for the official record, the Panel 
encourages that individuals and interested groups consider submitting 
written statements instead of addressing the Panel.

    Dated: May 5, 2017.
Aaron Siegel,
Alternate OSD Federal Register Liaison Officer, Department of Defense.
[FR Doc. 2017-09450 Filed 5-9-17; 8:45 am]
BILLING CODE 5001-06-P